Dyne Therapeutics Ownership | Who Owns Dyne Therapeutics?

Dyne Therapeutics Ownership Summary

Dyne Therapeutics is owned by 144.98% institutional investors, 0.28% insiders. T. rowe price investment management is the largest institutional shareholder, holding 23.97% of DYN shares. T. Rowe Price US Small-Cap Core Equity is the top mutual fund, with 4.25% of its assets in Dyne Therapeutics shares.

DYN Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Dyne Therapeutics	144.98%	0.28%	-45.26%
Sector	Healthcare Stocks	35.34%	11.88%	52.77%
Industry	Biotech Stocks	35.37%	11.83%	52.80%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
T. rowe price investment management	30.79M	23.97%	$558.15M
Janus henderson group	13.65M	10.63%	$247.43M
Blackrock	7.39M	9.11%	$260.69M
Blackrock funding, inc. /de	11.70M	9.11%	$212.12M
Vanguard group	11.22M	7.91%	$219.38M
Atlas venture life science advisors	9.13M	7.11%	$165.54M
Fmr	8.91M	6.94%	$161.52M
Orbis allan gray	6.76M	5.26%	$122.60M
State street	6.65M	5.18%	$120.63M
Perceptive advisors	4.67M	3.63%	$84.65M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Atlas venture life science advisors	9.13M	20.95%	$165.54M
Mpm asset management	682.38K	19.40%	$8.63M
Fcpm iii services b.v.	4.64M	11.66%	$84.20M
University of wisconsin foundation	484.75K	7.80%	$8.79M
Palo alto investors lp	1.65M	4.58%	$29.97M
Saturn v capital management	966.61K	3.17%	$17.52M
Tcg crossover management	4.62M	2.39%	$83.67M
Vivo capital	1.56M	2.36%	$28.24M
Vestal point capital, lp	4.00M	2.03%	$72.52M
Bioimpact capital	1.41M	1.97%	$25.53M

Top Buyers

Holder	Shares	% Assets	Change
T. rowe price investment management	30.79M	0.38%	13.25M
Vestal point capital, lp	4.00M	2.03%	3.88M
Fmr	8.91M	0.01%	2.34M
Blackrock	7.39M	0.01%	2.00M
Orbis allan gray	6.76M	0.52%	1.96M

Top Sellers

Holder	Shares	% Assets	Change
Ra capital management	-	-	-9.71M
Adage capital partners gp	1.00M	0.03%	-4.17M
Holocene advisors, lp	-	-	-2.35M
Jefferies financial group	-	-	-1.80M
Siren	2.23M	1.12%	-1.27M

New Positions

Holder	Shares	% Assets	Change	Value
Paradigm biocapital advisors lp	1.90M	0.68%	1.90M	$24.02M
Fiera capital	1.38M	0.09%	1.38M	$25.03M
Vanguard fiduciary trust	947.44K	0.00%	947.44K	$17.18M
Axa investment managers	163.23K	0.01%	163.23K	$2.06M
Man group	95.68K	0.00%	95.68K	$1.73M

Sold Out

Holder	Change
Dunhill financial	-1.00
Nelson, van denburg & campbell wealth management group	-9.00
J.safra asset management	-11.00
Cva family office	-12.00
Srs capital advisors	-18.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	229	-4.58%	186,215,369	4.65%	144	0.92%	139	-9.74%	60	7.14%
Dec 31, 2025	48	-77.78%	17,667,612	-88.66%	12	0.07%	33	-77.40%	8	-80.49%
Sep 30, 2025	56	-72.00%	16,926,024	-86.84%	14	0.12%	39	-66.95%	9	-82.69%
Jun 30, 2025	198	-5.71%	128,546,973	5.45%	112	0.92%	116	-10.08%	52	15.56%
Mar 31, 2025	25	-87.86%	30,059,507	-73.06%	27	0.22%	15	-85.98%	6	-90.32%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
T. Rowe Price US Small-Cap Core Equity	7.01M	4.25%	1.57M
T. Rowe Price Small-Cap Stock	7.01M	4.25%	1.50M
Vanguard Total Stock Mkt Idx Inv	4.65M	2.82%	29.74K
T. Rowe Price Small-Cap Value	4.63M	2.80%	1.78M
Vanguard US Total Market Shares ETF	2.65M	2.35%	2.40K
State Street® SPDR® S&P® Biotech ETF	3.83M	2.32%	-37.90K
T. Rowe Price Instl Small-Cap Stock	3.81M	2.31%	797.50K
T. Rowe Price U.S. SC Core Eq Tr-D	3.38M	2.05%	819.54K
T. Rowe Price Capital Appreciation	3.28M	1.99%	3.28M
iShares Russell 2000 ETF	3.13M	1.89%	26.37K

Recent Insider Transactions

Date	Name	Role	Activity	Value
May 13, 2026	Friedl-Naderer Johanna	Chief Commercial Officer	Sell	$4.19K
May 13, 2026	Kerr Douglas	Chief Medical Officer	Sell	$28.72K
May 13, 2026	Lucera Erick	Chief Financial Officer	Sell	$26.59K
May 13, 2026	Cox John	CEO & President	Sell	$60.79K
May 04, 2026	Rhodes Jason P	-	Sell	$56.45K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	-	60
2026 Q1	3	8
2025 Q4	-	3
2025 Q3	1	5
2025 Q2	-	3

DYN Ownership FAQ

Who Owns Dyne Therapeutics?

Dyne Therapeutics shareholders are primarily institutional investors at 144.98%, followed by 0.28% insiders and -45.26% retail investors. The average institutional ownership in Dyne Therapeutics's industry, Biotech Stocks , is 35.37%, which Dyne Therapeutics exceeds.

Who owns the most shares of Dyne Therapeutics?

Dyne Therapeutics’s largest shareholders are T. rowe price investment management (30.79M shares, 23.97%), Janus henderson group (13.65M shares, 10.63%), and Blackrock (7.39M shares, 9.11%). Together, they hold 43.71% of Dyne Therapeutics’s total shares outstanding.

Does Blackrock own Dyne Therapeutics?

Yes, BlackRock owns 9.11% of Dyne Therapeutics, totaling 7.39M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 260.69M$. In the last quarter, BlackRock increased its holdings by 2M shares, a 37.05% change.

Who is Dyne Therapeutics’s biggest shareholder by percentage of total assets invested?

Atlas venture life science advisors is Dyne Therapeutics’s biggest shareholder by percentage of total assets invested, with 20.95% of its assets in 9.13M Dyne Therapeutics shares, valued at 165.54M$.

Who is the top mutual fund holder of Dyne Therapeutics shares?

T. Rowe Price US Small-Cap Core Equity is the top mutual fund holder of Dyne Therapeutics shares, with 4.25% of its total shares outstanding invested in 7.01M Dyne Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools